NeOnc Technologies Holdings Inc. (NTHI) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.26 (+4.49% 1D, market cap $92.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NTHI ranks #749 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NTHI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLYX (Polaryx Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $93.2M). Among the 5-stock peer group, NTHI leads on earnings multiple (N/A) while NTHI leads on capital efficiency (-35.0% ROIC).
Per NTHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001979414), NeOnc Technologies Holdings Inc. generated $40.0K in revenue (-51.8% YoY), -$62.1M in net income, and -$20.4M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While NTHI currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.45) and Max Pain ($3.42) forces dealer call-delta covering toward $12.60.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NeOnc Technologies Holdings Inc. (NTHI) surged +4.49% to $3.26, trading at 8% of its 52-week range ($2.5 – $12). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that
Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics (NASDAQ:LUCD)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -51.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NTHI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NTHI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, NeOnc Technologies Holdings Inc. (NTHI) ranks #749 by composite RQD confidence (33/100, grade E) and #672 by equity capitalization ($92.9M). Within this direct 5-issuer industry benchmark cohort, NTHI leads on earnings valuation at N/A trailing P/E, while NTHI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with NTHI at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NTHI
ACTIVE
NeOnc Technologies Holdings Inc. | E | 33/100 | — | — | -35.0% | +4.49% | $92.9M | Benchmark Subject |
| PLYX Polaryx Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -5.91% | $92.7M | /plyx-vs-nthi → |
| RTSN Retension Pharmaceuticals Inc. | D | 48/100 | — | — | — | -3.97% | $93.2M | /rtsn-vs-nthi → |
| COYA Coya Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -9.30% | $93.4M | /coya-vs-nthi → |
| GNLX Genelux Corporation | E | 29/100 | — | — | -35.0% | -0.95% | $95.0M | /gnlx-vs-nthi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeOnc Technologies Holdings Inc. (NTHI) reported GAAP revenue of $40.0K (-51.8% vs. FY2024 revenue of $83.0K ) , GAAP net income of -$62.1M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (-383.3% YoY). On the balance sheet, NTHI closed FY2025 with $2.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.0K | -$62.1M | -$20.4M | -$20.4M | $2.8M | — |
| FY2024 (FY) | 2024-12-31 | $83.0K | -$11.9M | -$4.2M | -$4.2M | $3.4M | — |
As of 2026-11-02, NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.26 (+4.49% 1D, market cap $92.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NTHI ranks #749 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NTHI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLYX (Polaryx Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $93.2M). Among the 5-stock peer group, NTHI leads on earnings multiple (N/A) while NTHI leads on capital efficiency (-35.0% ROIC).
Per NTHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001979414), NeOnc Technologies Holdings Inc. generated $40.0K in revenue (-51.8% YoY), -$62.1M in net income, and -$20.4M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NTHI last traded at $3.26 (+4.49% on volume of 131,704 shares), positioning the stock -5.51% below its 50-day simple moving average ($3.45) and -40.07% below its 200-day simple moving average ($5.44). Across its 52-week range of $2.50 to $12.00, NTHI sits at the 8.0% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.85 to $3.67).
Why NTHI Stock surged +4.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, NTHI scores 33 out of 100 and receives a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 7/20 (ROIC of -35%; FCF yield of -21.93%), indicating the business is consuming rather than generating cash. Whale/13F Flow scores 10/20, reflecting institutional accumulation and options positioning that is moderate rather than decisive. Insider Conviction scores 3/20 on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar and a signal of limited insider confidence. Macro Regime Fit scores 6/20 with a Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 7/20 with an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and a Debt/Equity ratio of 0.5. For a prospective investor evaluating the stock today, the rating points to negative operating economics, weak insider signaling, and forensic red flags, which together weigh heavily against the upside case. Any potential upside would depend on a sustained operating turnaround that the reported financials do not yet show.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-58.2M | $-62.1M | N/A | $-20.4M | $0.1M | N/A |
| FY 2024 | $0.1M | $-7.1M | $-11.9M | N/A | $-4.2M | $0.1M | N/A |
Per the SEC financials, operating losses widened from $-7.1M in FY 2024 to $-58.2M in FY 2025, and net income fell from $-11.9M to $-62.1M. Operating, net, and gross margins are reported as -60%, -60%, and 0% respectively per the market data section, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with a Debt/Equity ratio of 0.5. Cash is reported at $0.1M in both periods, and debt is N/A in the financial data.
Per the recent news wire, catalysts center on clinical and scientific communications: a study in which 48.9% were alive without worsening disease at six months, a pediatric case report of a patient breathing without a ventilator, and a planned presentation of NEO100 and NEO212 program data at the 31st Annual Meeting of the Society for Neuro-Oncology. Other items reference market action, including a report of breaking above key resistance on strong volume ahead of a Fox Business appearance and Abu Dhabi milestones. All five items are rated YELLOW. Per the Butterfly Supply-Chain Graph, no proprietary signals are present (supply_chain: NONE; butterfly_links: none; proprietary_signals: none). Risk watch items include the widening operating losses in the SEC financials and the weak Insider Conviction pillar, which are not offset by any signal in the graph.
Real-time company headlines, analyst actions, and sector developments for NeOnc Technologies Holdings Inc. (NTHI) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Welcome to the NTHI (NeOnc Technologies Holdings Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on NTHI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless NeOnc Technologies Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on NTHI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.12 (52-wk range $2.80 - $3.48), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).